nach oben

Erschienen in:

18.09.2023 | Case Study

Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses

verfasst von: Ai Seon Kuan, Chi-Lu Chiang, Hsiu-Mei Wu, Huai-Che Yang, Ching-Jen Chen, Chung-Jung Lin, Wan-Yuo Guo, David Hung-Chi Pan, Wen-Yuh Chung, Cheng-Chia Lee

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To examine the differential effects of SRS and TKI on EGFR-mutated NSCLC patients with brain metastases (BMs) and outcomes following continuation of the same TKI agent in case of new BMs.

Methods

This study included 608 NSCLC patients (2,274 BMs) while meta-analyses included 1,651 NSCLC patients (> 3,944 BMs). Overall survival (OS) and intracranial progression free survival (iPFS) were estimated using Kaplan-Meier methods. Hazard ratios (95% CI) of prognostic factors were estimated using Cox regression models.

Results

The median OS/iPFS (95% CI) (months) for patients with wildtype EGFR/ALK, EGFR mutations, and ALK rearrangements were 17.7 (12.9–23.6)/12.1 (9.8–15.6), 28.9 (23.8–33.3)/17.7 (14.8–21.2), and 118.0 (not reached)/71.7 (15.1–not reached), respectively. In EGFR-mutated patients, meta-analyses combining our data showed significantly improved OS and iPFS of patients who received SRS and TKI (OS:35.1 months, iPFS:20.0 months) when compared to those who have SRS alone (OS:20.8 months, iPFS:11.8 months) or TKI alone (OS:24.3 months, iPFS:13.8 months). Having SRS for newly diagnosed BMs while keeping the existing TKI agent yielded OS (30.0 vs. 32.1 months, p = 0.200) non-inferior to patients who started combined SRS and TKI therapy for their newly diagnosed NSCLC with BMs. Multivariable analyses showed that good performance score and TKI therapy were associated with improved outcomes.

Conclusions

Combined SRS and TKI resulted in favorable outcomes in EGFR-mutated NSCLC patients with newly diagnosed BMs. Continuation of the same TKI agent plus SRS in case of new brain metastases yielded good clinical outcomes and may be considered a standard-of-care treatment.

Nur mit Berechtigung zugänglich

Li L, Luo S, Lin H et al (2017) Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. J Thorac Dis 9:2510–2520CrossRefPubMedPubMedCentral

Shin DY, Na II, Kim CH et al (2014) EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 9:195–199CrossRefPubMed

Zhang I, Zaorsky NG, Palmer JD et al (2015) Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 16:e510–521CrossRefPubMed

Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967CrossRefPubMed

Jiang T, Min W, Li Y et al (2016) Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med 5:1055–1065CrossRefPubMedPubMedCentral

Singh R, Lehrer EJ, Ko S et al (2020) Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: a systematic review and meta-analysis of multidisciplinary approaches. Radiother Oncol 144:165–179CrossRefPubMed

Chiou GY, Chiang CL, Yang HC et al (2021) Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases. J Neurosurg ; 1–8

Magnuson WJ, Lester-Coll NH, Wu AJ et al (2017) Management of brain metastases in tyrosine kinase Inhibitor-Naïve epidermal growth factor receptor-mutant non-small-cell Lung Cancer: a retrospective multi-institutional analysis. J Clin Oncol 35:1070–1077CrossRefPubMed

Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of Radiosurgery alone vs Radiosurgery with Whole Brain Radiation Therapy on cognitive function in patients with 1 to 3 brain metastases: a Randomized Clinical Trial. JAMA 316:401–409CrossRefPubMedPubMedCentral

10.

Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12:627–642CrossRefPubMed

11.

Barnet MB, O’Toole S, Horvath LG et al (2017) EGFR-Co-Mutated Advanced NSCLC and Response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 12:585–590CrossRefPubMed

12.

De Pas T, Toffalorio F, Manzotti M et al (2011) Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 6:1895–1901CrossRefPubMed

13.

Massarelli E, Johnson FM, Erickson HS et al (2013) Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer 80:235–241CrossRefPubMed

14.

Doherty MK, Korpanty GJ, Tomasini P et al (2017) Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. Radiother Oncol 123:195–202CrossRefPubMed

15.

Lee CC, Hsu SPC, Lin CJ et al (2019) Epidermal growth factor receptor mutations: association with favorable local tumor control following Gamma Knife radiosurgery in patients with non-small cell lung cancer and brain metastases. J Neurosurg ; 1–8

16.

Lee CC, Yen CP, Xu Z et al (2014) Large intracranial metastatic tumors treated by Gamma Knife surgery: outcomes and prognostic factors. J Neurosurg 120:52–59CrossRefPubMed

17.

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71CrossRefPubMedPubMedCentral

18.

Wells GA, Shea B, O’Connell D et al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In

19.

Byeon S, Ham JS, Sun JM et al (2016) Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Med Oncol 33:97CrossRefPubMedPubMedCentral

20.

Chen Y, Yang J, Li X et al (2016) First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma. Cancer Sci 107:1800–1805CrossRefPubMedPubMedCentral

21.

Gerber NK, Yamada Y, Rimner A et al (2014) Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys 89:322–329CrossRefPubMedPubMedCentral

22.

He ZY, Li MF, Lin JH et al (2019) Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. Cancer Manag Res 11:2129–2138CrossRefPubMedPubMedCentral

23.

Iuchi T, Shingyoji M, Sakaida T et al (2013) Phase II trial of gefitinib alone without radiation therapy for japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82:282–287CrossRefPubMed

24.

Jia F, Cheng X, Zeng H et al (2019) Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer. J buon 24:578–584PubMed

25.

Kim HJ, Kim WS, Kwon DH et al (2015) Effects of an epithelial growth factor receptor-tyrosine kinase inhibitor add-on in stereotactic radiosurgery for Brain Metastases originating from Non-Small-Cell Lung Cancer. J Korean Neurosurg Soc 58:205–210CrossRefPubMedPubMedCentral

26.

Park SJ, Kim HT, Lee DH et al (2012) Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77:556–560CrossRefPubMed

27.

Wang C, Lu X, Zhou Z et al (2019) The efficacy of Upfront Intracranial Radiation with TKI compared to TKI alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. J Cancer 10:1985–1990CrossRefPubMedPubMedCentral

28.

Wang W, Song Z, Zhang Y (2018) Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis. Arch Med Sci 14:1298–1307CrossRefPubMedPubMedCentral

29.

Yang WC, Xiao F, Shih JY et al (2018) Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol 126:368–374CrossRefPubMed

30.

Zhu Q, Sun Y, Cui Y et al (2017) Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). Oncotarget 8:13304–13311CrossRefPubMedPubMedCentral

31.

Chang CY, Chen CY, Chang SC et al (2021) Efficacy and prognosis of first-line EGFR-Tyrosine kinase inhibitor treatment in older adults including poor performance status patients with EGFR-Mutated non-small-cell Lung Cancer. Cancer Manag Res 13:7187–7201CrossRefPubMedPubMedCentral

32.

Cheng WC, Shen YC, Chien CR et al (2022) The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: a real-world study from Taiwan. Thorac Cancer 13:1505–1512CrossRefPubMedPubMedCentral

33.

Miyawaki E, Kenmotsu H, Mori K et al (2019) Optimal sequence of local and EGFR-TKI therapy for EGFR-Mutant Non-Small Cell Lung Cancer with Brain Metastases stratified by number of Brain Metastases. Int J Radiat Oncol Biol Phys 104:604–613CrossRefPubMed

34.

Su PL, Wu YL, Chang WY et al (2018) Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Ther Adv Med Oncol 10:1758835918797589CrossRefPubMedPubMedCentral

35.

Yamamoto M, Serizawa T, Shuto T et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15:387–395CrossRefPubMed

36.

Chang EL, Wefel JS, Hess KR et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044CrossRefPubMed

37.

Kobayashi S, Canepa HM, Bailey AS et al (2013) Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8:45–51CrossRefPubMedPubMedCentral

38.

Yip PY, Yu B, Cooper WA et al (2013) Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. J Thorac Oncol 8:408–414CrossRefPubMed

39.

Tam IY, Leung EL, Tin VP et al (2009) Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 8:2142–2151CrossRefPubMed

40.

Camidge DR, Kim HR, Ahn MJ et al (2021) Brigatinib Versus Crizotinib in ALK inhibitor-naive Advanced ALK-Positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol 16:2091–2108CrossRefPubMed

41.

Johung KL, Yeh N, Desai NB et al (2016) Extended survival and prognostic factors for patients with ALK-Rearranged non-small-cell Lung Cancer and Brain Metastasis. J Clin Oncol 34:123–129CrossRefPubMed

42.

Zou Z, Xing P, Hao X et al (2022) Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study. BMC Med 20:12CrossRefPubMedPubMedCentral

Titel: Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses
verfasst von: Ai Seon Kuan
Chi-Lu Chiang
Hsiu-Mei Wu
Huai-Che Yang
Ching-Jen Chen
Chung-Jung Lin
Wan-Yuo Guo
David Hung-Chi Pan
Wen-Yuh Chung
Cheng-Chia Lee
Publikationsdatum: 18.09.2023
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04452-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial

Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas

Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors

Age and sex disparities in Latin-American adults with gliomas: a systematic review and meta-analysis

Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients